Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and LarmorBio, Inc. ("LarmorBio") today announced that Velocity Bioworks, Valion's wholly owned biologics contract development and manufacturing organization ("CDMO") subsidiary, has successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR™ platform.

• BioScan-NMR™ is being developed to create a new class of process analytical technology ("PAT") for biologics manufacturing.
• The initial feasibility evaluation demonstrated that nuclear magnetic resonance ("NMR") measurements have the potential to track microbial growth during a fermentation process.
• Building on that foundation, LarmorBio is developing a real-time, continuous monitoring platform designed to:
  • Bring biological visibility directly into the manufacturing process, with the potential to detect deviations earlier
  • Reduce the risk of batch failures
  • Lower manufacturing costs
  • Enable more consistent and efficient production

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.